Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS OLE long-term cenerimod extension in systemic lupus erythematosus
jRCT2031260475Phase 3Not yet recruiting
- Sponsor
- Viatris
- Start
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Primary endpoints: Treatment-emergent adverse events, Adverse events leading to permanent discontinuation and 5 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031260475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260475.